📰 Eric Bouffet News
Eric Bouffet News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Eric Bouffet. Real-time updates on events, politics, business and more.
April 26, 2024
Tovorafenib is the first systemic therapy to be approved for the treatment of pediatric patients who have low-grade glioma with BRAF rearrangements or fusions.
September 25, 2023
Dabrafenib plus trametinib results in significantly more responses and longer progression-free survival than standard chemotherapy for pediatric patients with low-grade glioma with BRAF V600 mutations.
March 16, 2023
New approval based on TADPOLE trial showing overall response rate (ORR) of 47% and median progression-free survival (mPFS) of 20.1 months for Tafinlar + Mekinist compared to 11% ORR and 7.4 months mPFS
March 16, 2023
Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma, the most common pediatric brain cancer
June 6, 2022
Combining dabrafenib with trametinib markedly improved response rates and delayed progression over standard-of-care chemotherapy in pediatric BRAF V600-mutant low-grade glioma in a phase 2 trial.
October 21, 2021
From left: Amar Gajjar, M.D, Pediatric Medicine chair; Paul Northcott, Ph.D., Developmental Neurobiology; Kyle Smith, Ph.D., Developmental